ENDP - Endo International plc
| Previous Close | 11.22 |
| Open | 11.26 |
| Bid | 11.10 x 1000 |
| Ask | 11.30 x 100 |
| Day's Range | 11.09 - 11.34 |
| 52 Week Range | 5.27 - 12.54 |
| Volume | 1,829,672 |
| Avg. Volume | 6,386,154 |
| Market Cap | 2.495B |
| Beta | -0.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -10.60 |
| Earnings Date | Aug 8, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.09 |
- PR Newswire•21 hours ago
Endo to Announce Second-Quarter 2018 Financial Results
DUBLIN , July 20, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) will announce its second-quarter 2018 financial results on August 8, 2018 and members of its senior management team will host ...
- Bloomberg•2 days ago
Drug Firms Blame Opioid Crisis on Illicit Websites, Dealers
Two pharmaceutical companies say the real culprits in the opioids epidemic are illegal dealers of the painkillers and want them to be on the hook financially for any damages potentially assessed against drugmakers. Endo International Plc and Mallinckrodt Plc sued a host of convicted drug dealers and Internet sites this week for illegally offering opioids. Among them: RxCash.Biz, which offers misbranded opioids online, an Italian man indicted for of operating so-called pill mills, and a Tennessee resident who’s serving 10 years for possessing fentanyl with an intent to distribute.
- ACCESSWIRE•2 days ago
Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Endo International
NEW YORK, NY / ACCESSWIRE / July 19, 2018 / U.S. equities closed mostly higher Wednesday, as investors welcomed quarterly earnings and positive signs of a rapidly growing domestic economy. The Dow Jones ...
Markit•2 days agoSee what the IHS Markit Score report has to say about Endo International PLC.
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on July 17. Over the last one-month, outflows of investor capital in ETFs holding ENDP totaled $2.05 billion.
Markit•7 days agoSee what the IHS Markit Score report has to say about Endo International PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ENDP totaled $2.43 billion.
Market Realist•9 days agoWhat Endo International’s Valuation Trend Indicates
Endo International’s (ENDP) U.S. Branded – Sterile Injectables segment includes branded sterile injectable products such as Vasostrict, Adrenalin, and Aplisol, and generic sterile injectable products such as ephedrine sulphate injection and neostigmine methylsulfate injection. Revenues from this segment increased from $172.17 million in Q1 2017 to $215.85 million in Q1 2018.
Market Realist•9 days agoEndo’s Generic and International Segments Declined in Q1 2018
Under Endo International’s (ENDP) established products, Percocet sales increased from $30.94 million in Q1 2017 to $31.97 million in Q1 2018. The increase was attributable to higher prices, partially offset by a decline in volume. Voltaren gel sales, on the other hand, decreased from $14.27 million in Q1 2017 to $11.32 million in Q1 2018 due to lower prices resulting from generic competition. Sales from other established products also decreased, from $64.48 million in Q1 2017 to $45.03 million in Q1 2018.
Market Realist•9 days agoAnalyzing Endo International’s Financial Performance
Endo International (ENDP) generated revenues of $700.5 million in the first quarter compared to $1.04 billion in Q1 2017. Endo International incurred a cost of revenues of $403.59 million in the first quarter compared to $668.96 million in Q1 2017. Its gross profit was $296.93 million in the first quarter compared to $368.64 million in Q1 2017.
Market Realist•9 days agoEndo International’s Specialty and Established Products in Q1
Endo International’s (ENDP) net interest expense increased from $111.9 million in Q1 2017 to $123.9 million in Q1 2018. While the company received an income tax benefit of $11.9 million in Q1 2017, it had an income tax expense of $15.49 million in Q1 2018. That led to an increase in its net loss from $173.83 million in Q1 2017 to $505.48 million in Q1 2018. That translated to a net loss per share of $2.26 in Q1 2018 compared to a net loss per share of $0.78 in Q1 2017.
Market Realist•9 days agoWhat Analysts Think of Endo International
Of the 19 analysts covering Endo International (ENDP) stock in July, four of them have given the stock a “buy” or higher rating, 14 have given it a “hold,” and one has given it a “sell.” The mean rating for the stock is 2.74 with a target price of $8.53. Sixteen of the 20 analysts covering Abbott Laboratories (ABT) in July have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.8 with a target price of $69.
- ACCESSWIRE•11 days ago
Today's Research Reports on Trending Tickers: Endo International and GW Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / July 10, 2018 / U.S. equities continued to push higher on Monday, as strong economic data counters worries on rising trade tensions. The Dow Jones Industrial Average advanced ...
- ACCESSWIRE•12 days ago
Today's Research Reports on Trending Tickers: OPKO Health and Endo International
NEW YORK, NY / ACCESSWIRE / July 9, 2018 / U.S. equities posted solid gains on Friday, ending the week on a positive note, supported by a stronger-than-expected jobs report. The Dow Jones Industrial Average ...
- ACCESSWIRE•12 days ago
Complimentary Technical Snapshots on Teva Pharma Industries and Three More Drug Makers Stocks
Stock Research Monitor: DEPO, DRRX, and ENDP LONDON, UK / ACCESSWIRE / July 9, 2018 / If you want a free Stock Review on TEVA sign up now at www.wallstequities.com/registration . In today's pre-market ...
Markit•14 days agoSee what the IHS Markit Score report has to say about Endo International PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ENDP totaled $3.08 billion.
- Zacks•18 days ago
Is Endo International a Great Stock for Value Investors?
Let???s see if Endo International (ENDP) stock is a good choice for value-oriented investors right now from multiple angles.
- PR Newswire•19 days ago
Endo Begins Shipment of Authorized Generic Version of Colcrys® (colchicine, USP) in the United States
DUBLIN, July 2, 2018 /PRNewswire/ -- Endo International plc (ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping an authorized generic version of Takeda Pharmaceutical's Colcrys® (colchicine, USP) 0.6 mg tablets. Endo's subsidiary, Endo Ventures Limited, entered into an exclusive U.S. supply and distribution agreement with Takeda Pharmaceuticals U.S.A., allowing Par to launch and distribute an authorized generic of the product.
- Zacks•22 days ago
Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?
Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.
- ACCESSWIRE•22 days ago
Today's Research Reports on Trending Tickers: Endo International and Sangamo Therapeutics
NEW YORK, NY / ACCESSWIRE / June 29, 2018 / U.S. markets rebounded Thursday on the strength of the financial and technology sectors. The Dow Jones Industrial Average jumped 0.41 percent to close at 24,216.05, ...
- Benzinga•23 days ago
Endo Wins Citi Upgrade On Positive Catalysts, Cellulite Treatment Opportunity
Endo International PLC (NASDAQ: ENDP ) is now trading at a favorable risk-reward profile and investors should be constructive on the stock, according to Citi. The Analyst Citi's Liav Abraham upgraded Endo ...
Markit•25 days agoSee what the IHS Markit Score report has to say about Endo International PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- InvestorPlace•last month
Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play
The U.S. government is shifting its focus from accusing drug companies of overcharging to encouraging the marketplace to operate more competitively. On May 31, FDA Commissioner Scott Gottlieb, announced a draft guidance that will limit drug companies in delaying generics to market. Previously, generics needed to negotiate with branded firms.
- Market Realist•last month
Why Endo International Stock Rose 5.5% on June 12
On June 11, after the markets closed, Endo International (ENDP) announced that its subsidiaries Endo Pharmaceuticals and Auxilium Pharmaceuticals have entered into a master settlement agreement. This agreement is intended to resolve all known TRT (testosterone replacement therapy) product liability claims the company faces. The company said that the agreement isn’t expected to increase Endo’s product liability reserve, as the company has already recorded an accrual for the settlement in Q4 2017.
- CNBC•last month
Cramer's lightning round: I can't get people to buy Alibaba's stock
Jim Cramer laments investors' distaste in the e-commerce conglomerate while taking questions in the lightning round.
- American City Business Journals•last month
Endo executes master settlement agreement to resolve testosterone lawsuits
Two Endo International subsidiaries, Endo Pharmaceuticals and Auxilium Pharmaceuticals, have executed a definitive master settlement agreement to resolve all known testosterone replacement therapy product liability claims against the company. The agreement does not involve any admission of wrongdoing or liability by Endo, which is based in Dublin, Ireland, and has its U.S. headquarters in Malvern, Pa. Endo and its subsidiaries are defendants in more than 1,200 lawsuits filed by users of testosterone replacement therapy, who have alleged the drug maker did not properly disclose health risks associated with taking such products. Endo was one of several testosterone replacement therapy manufacturers sued in such cases.
- PR Newswire•last month
Endo Announces Master Settlement Agreement Allowing for Resolution of Known Testosterone Replacement Therapy Product Liability Claims and Entry of Significant Case Management Order
DUBLIN , June 11, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP ) today announced that its subsidiaries Endo Pharmaceuticals Inc. and Auxilium Pharmaceuticals, LLC (collectively, "Endo" ...
